SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart failure medications, researchers reported at San Antonio Breast Cancer Symposium (SABCS) 2015.
By Kate Johnson – Medscape Medical News, Conference News
December 15, 2015
